Amro chemical fiber provides a solution for reversing liver fibrosis

Based on the national "Twelfth Five-Year Plan" and "Thirteenth Five-Year Plan" major science and technology projects and a series of clinical studies in the efficacy and safety of excellent performance, coupled with Academician Zhuang Hui, Professor Liu Xueen team's perfect explanation of drug action mechanism, Anluo chemical fiber has been recognized and recommended by major guidelines and consensus related to liver disease in China, creating a new clinical treatment standard. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 edition), Guidelines for the Prevention and Treatment of Esophageal and Gastric varices Bleeding with Portal Hypertension in Cirrhosis (2022 edition), Guidelines for the Diagnosis and Treatment of Cirrhosis (2019 edition), Guidelines for the Diagnosis and Treatment of Ascites and Related Complications in Cirrhosis (2017 edition), Guidelines for the Clinical Diagnosis and Treatment of Traditional Chinese Medicine -- Liver Fibrosis (2019 edition), etc National guidelines all recommend its use to relieve or reverse liver fibrosis. The guidance of the major guidelines for clinical standardized treatment will further enhance the normative and therapeutic level of liver fibrosis treatment in China and improve the benefit of patients.

Amro Chemical fiber participated in the COVID-19 traditional Chinese medicine emergency project

Based on the perfect mechanism and outstanding efficacy of amro chemical fiber against liver fibrosis, the National Administration of Traditional Chinese Medicine launched the safety and effectiveness analysis of AmRO chemical fiber in the treatment of patients recovering from Covid-19, using a prospective, multi-center, open, randomized and controlled study. With Peking University Hospital as the core, Wuhan Pulmonary Hospital, Ezhou Central Hospital, the First Affiliated Hospital of Bengbu Medical College, Fuyang Second People's Hospital, Guangzhou Eighth Hospital and other clinical units gave amro chemical fiber treatment (66 cases) and basic treatment (26 cases) to patients with negative nucleic acid test after treatment of Covid-19 infection and pulmonary fibrosis indicated by CT images. The results showed that after 6 months of treatment, the lung CT scores of patients in the amro chemical fiber group were significantly decreased compared with baseline (P=0.046), and the completion rate of 6-minute walking test was significantly increased compared with baseline (P=0.002). The standard treatment group showed no significant difference from baseline, bringing more weapons to the fight against COVID-19.